325 related articles for article (PubMed ID: 31664442)
1. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
Conti RM; Nikpay SS; Buntin MB
JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
[TBL] [Abstract][Full Text] [Related]
2. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
3. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
Li Y; Xu S
JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
[TBL] [Abstract][Full Text] [Related]
4. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
Clark BL; Hou J; Chou CH; Huang ES; Conti R
Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
[TBL] [Abstract][Full Text] [Related]
5. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
[TBL] [Abstract][Full Text] [Related]
6. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
Conti RM; Bach PB
Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
[TBL] [Abstract][Full Text] [Related]
7. Relationship between initiation of 340B participation and hospital safety-net engagement.
Nikpay SS; Buntin MB; Conti RM
Health Serv Res; 2020 Apr; 55(2):157-169. PubMed ID: 32187392
[TBL] [Abstract][Full Text] [Related]
8. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
Ruley M; Belcher M; Sayre H; Coustasse A
Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
[TBL] [Abstract][Full Text] [Related]
9. Using 340B drug discounts to provide a financially sustainable medication discharge service.
Wu T; Williams C; Vranek K; Mattingly TJ
Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
[TBL] [Abstract][Full Text] [Related]
10. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
[TBL] [Abstract][Full Text] [Related]
12. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
Health Resources and Services Administration, Department of Health and Human Services (HHS)
Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
[TBL] [Abstract][Full Text] [Related]
13. Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.
Jung J; Xu WY; Kalidindi Y
Health Serv Res; 2018 Oct; 53(5):3528-3548. PubMed ID: 29355925
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
Zeta LM
Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
[TBL] [Abstract][Full Text] [Related]
15. A comparison of medication access services at 340B and non-340B hospitals.
Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
[TBL] [Abstract][Full Text] [Related]
16. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
Lee CH; Chang J; McCombs J
J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
[TBL] [Abstract][Full Text] [Related]
17. US Hospital Service Availability and New 340B Program Participation.
Owsley KM; Hasnain-Wynia R; Rooks RN; Tung GJ; Mays GP; Lindrooth RC
JAMA Health Forum; 2024 May; 5(5):e240833. PubMed ID: 38700853
[TBL] [Abstract][Full Text] [Related]
18. Consequences of the 340B Drug Pricing Program.
Desai S; McWilliams JM
N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
[TBL] [Abstract][Full Text] [Related]
19. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
Mulligan K; Romley JA; Myerson R
BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
[TBL] [Abstract][Full Text] [Related]
20. 340B program presents opportunities--and challenges.
Keough CL; Webster SA
Healthc Financ Manage; 2009 Nov; 63(11):42-4, 46, 48. PubMed ID: 19891397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
